Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2022

Revenue Recognition

Schedule of disaggregation of revenue

	Three Months Ended				Nine Months Ended
	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021
Collaborative revenue
Vifor (KORSUVA injection profit sharing)	$	7,443	$	—	$	15,446	$	—
Maruishi		—		—		—		706
Total collaborative revenue	$	7,443	$	—	$	15,446	$	706
License and milestone fees
Vifor	$	—	$	20,031	$	15,000	$	20,031
Maruishi		—		—		—		1,192
Total license and milestone fees	$	—	$	20,031	$	15,000	$	21,223
Commercial supply revenue
Vifor (KORSUVA injection)	$	3,370	$	—	$	8,160	$	—
Total commercial supply revenue	$	3,370	$	—	$	8,160	$	—
Clinical compound revenue
Vifor (difelikefalin injection)	$	—	$	241	$	—	$	241
Maruishi		—		—		—		37
Total clinical compound revenue	$	—	$	241	$	—	$	278